bluebird bio (bluebird bio) Equity-to-Asset : 0.36 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. bluebird bio's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $222.54 Mil. bluebird bio's Total Assets for the quarter that ended in Sep. 2023 was $613.61 Mil. Therefore, bluebird bio's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was 0.36.

The historical rank and industry rank for bluebird bio's Equity-to-Asset or its related term are showing as below:

BLUE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31 Med: 0.78 Max: 0.92
Current: 0.36

During the past 12 years, the highest Equity to Asset Ratio of bluebird bio was 0.92. The lowest was 0.31. And the median was 0.78.

BLUE's Equity-to-Asset is ranked worse than
72.81% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs BLUE: 0.36

bluebird bio Equity-to-Asset Historical Data

The historical data trend for bluebird bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Equity-to-Asset Chart

bluebird bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

Get a 7-Day Free Trial

0.84

0.74

0.76

0.63

0.35

bluebird bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Equity-to-Asset	Get a 7-Day Free Trial															0.31	0.35	0.51	0.44	0.36

Competitive Comparison of bluebird bio's Equity-to-Asset

For the Biotechnology subindustry, bluebird bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bluebird bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where bluebird bio's Equity-to-Asset falls into.

bluebird bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

bluebird bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	196.343	/	554.902
	=	0.35

bluebird bio's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	222.536	/	613.608
	=	0.36

bluebird bio (NAS:BLUE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

bluebird bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of bluebird bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio (bluebird bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

BLUE:Mexico

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Executives

Richard A Colvin	officer: Chief Medical Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain	officer: President of SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk	officer: Chief Financial Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima	officer: Chief Commercial Officer, SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson	director	85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman	director	1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole	officer: SVP, Secy. & General Counsel	C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann	officer: Chief Regulatory Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman	officer: Chief Financial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten	officer: Chief Accounting Officer	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145